Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [3][5]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [5]. - It is claimed that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [5]. - The allegations include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [5]. Group 2: Financial Impact and Stock Performance - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [6]. - Following the announcement, West's stock price plummeted by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [7]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 between February 16, 2023, and February 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [3].

SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025. West is a medical supplies company that specializes in the development, manufacture, and distribution of elastomer-based supplies for the containment and administration of injectable drugs. For more information, submit a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 6, 2025 /PRNewswire/ -- Faruqi & Faruqi, ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the July 7, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE:WST) securities during the period from February 16, 2023, through February 12, 2025 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] On February 13, 2025, when West issued extremely weak 2025 r ...

LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR WEST INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired West Pharmaceutical Services, Inc. (“West Pharmaceutical” or the “Company”) (NYSE: WST) securities between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether West and certain of its offi ...